Osimertinib-induced interstitial lung disease in a patient with non-small cell lung cancer pretreated with nivolumab: A case report

Osimertinib (AZD9291) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor approved for EGFR-T790M-positive non-small cell lung cancer. A high incidence of interstitial lung disease (ILD) during combination treatment with osimertinib and anti-programmed cell death-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Clin Oncol
Main Authors: Takakuwa, Osamu, Oguri, Tetsuya, Uemura, Takehiro, Sone, Kazuki, Fukuda, Satoshi, Okayama, Minami, Kanemitsu, Yoshihiro, Ohkubo, Hirotsugu, Takemura, Masaya, Ito, Yutaka, Maeno, Ken, Niimi, Akio
Formato: Artigo
Idioma:Inglês
Publicado em: D.A. Spandidos 2017
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5543261/
https://ncbi.nlm.nih.gov/pubmed/28808573
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2017.1349
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados